Browse by Attribute
Browse by Column

Vectura Wins Additional USD 10m Patent Damages Against GSK

2019/09/18

A district court has upped Vectura’s award of USD 89.7 million in damages by USD 10million, after a jury trial earlier this year found that GlaxoSmithKline (GSK) has willfully infringed one of its patents.
 
In a press release on September 13, Vectura announced that the US District Court for the District of Delaware had granted its motion for a 3% royalty rate on all future US sales of the infringing products until Vectura’s patent expires in 2021.
 
The dispute concerns one of Vectura’s patents (US number 8,303,991), which GSK was found to have infringed with three of its “Ellipta” dry powder inhaler .
 
The patent covering the drugs was not included in a US licence agreement between the two companies, Vectura said.
 
The court also denied GSK’s motion for a new trial, and judgment of non-infringement.
 
 



Click Ranking

People watch


Chen Jun: Accumulation and Sublimation
It is lucky for Chen Jun to began his career in the IP industry 14 years ago when the first group of IP managers for businesses appeared on the stage in China and he has been in the industry.

Foxconn in Those Years
It was this “Whampoa Military Academy” for IP that educated China’s first batch of corporate IP management personnel. Many of these engineers left Foxconn in the years since.

more
2018 ANNUAL INVENTORY OF THE The Progress and Challenges of Copyright Industry in China Interview with Cheng Lingjun, Intellectual Property Director of Joyoung Co., Ltd. Interview with Chen Lingpei, General Manager of IP Division, Autodesk, Inc. (Greater China) Constant Accumulation Makes theLatecomers Surpass—Interview with Huang Lu, Director of IP Center of Humanwell Healthcare Between Lawyer and Manager —Interview with Xia Feng, the Chief IP Counsel of Greater China & Asia-Pacific, Honeywell (China) Patent Prosecution Highway and its Application Overview of EU copyright levy system – in the case of mobile phones